{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:53:51Z","timestamp":1789844031766,"version":"4.0.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jad-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jad.2018.04.047","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T12:22:47Z","timestamp":1523276567000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Meta-analysis: Second generation antidepressants and headache"],"prefix":"10.1016","volume":"236","author":[{"given":"Shilpa","family":"Telang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Olten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2018.04.047_bib0001","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/gps.4088","article-title":"Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Alaka","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0002","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","article-title":"Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study","volume":"10","author":"Asakura","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2018.04.047_bib0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group","volume":"175","author":"Baldwin","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0006","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0007","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0009","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","author":"Bose","year":"2008","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2018.04.047_bib0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20\u00a0mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0011","first-page":"130","article-title":"Clinical pharmacology of bupropion and imipramine in elderly depressives","volume":"44","author":"Branconnier","year":"1983","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.psy.41.2.153","article-title":"Use of mirtazapine as prophylactic treatment for migraine headache","volume":"41","author":"Brannon","year":"2000","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2018.04.047_bib0013","first-page":"519","article-title":"A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression","volume":"56","author":"Bremner","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/2013.jamapsychiatry.32","article-title":"The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial","volume":"70","author":"Brunoni","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00004714-198804000-00005","article-title":"Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression","volume":"8","author":"Byerley","year":"1988","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.jad.2018.04.047_bib0016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-199210002-00007","article-title":"Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies","volume":"7","author":"Chouinard","year":"1992","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-199604000-00003","article-title":"Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients","volume":"16","author":"Claghorn","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0018","first-page":"434","article-title":"Paroxetine versus placebo: a double-blind comparison in depressed patients","volume":"53","author":"Claghorn","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0019","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.4088\/JCP.12m08065","article-title":"Efficacy and safety of desvenlafaxine 50 mg\/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder","volume":"74","author":"Clayton","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.jad.2018.04.047_bib0020","first-page":"52","article-title":"Paroxetine in major depression: a double-blind trial with imipramine and placebo","volume":"53","author":"Cohn","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/10401239909147072","article-title":"Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment","volume":"11","author":"Coleman","year":"1999","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0022","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0149-2918(01)80090-4","article-title":"A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine","volume":"23","author":"Coleman","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2018.04.047_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/da.20695","article-title":"Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder","volume":"27","author":"Coric","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2018.04.047_bib0024","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2018.04.047_bib0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0149-2918(00)88317-4","article-title":"A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline","volume":"21","author":"Croft","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2018.04.047_bib0026","doi-asserted-by":"crossref","first-page":"e1291","DOI":"10.4088\/JCP.14m08992","article-title":"Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"75","author":"Croft","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0027","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","article-title":"Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder","volume":"24","author":"Davidson","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0028","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2018.04.047_bib0029","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","article-title":"Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia","volume":"61","author":"Davidson","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3956(02)00060-2","article-title":"Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression","volume":"36","author":"Detke","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2018.04.047_bib0031","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0032","first-page":"37","article-title":"[Headaches of tension and psychogenic headaches: assessment of the treatment with venlafaxine]","volume":"110","author":"Diukova","year":"2010","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"key":"10.1016\/j.jad.2018.04.047_bib0033","first-page":"84","article-title":"A double-blind placebo-controlled study of fluvoxamine and imipramine in depression","volume":"46","author":"Dominguez","year":"1985","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0034","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/head.12987","article-title":"Amitriptyline Dose and Treatment Outcomes in Specialty Headache Practice: A Retrospective Cohort Study","volume":"56","author":"Doyle Strauss","year":"2016","journal-title":"Headache"},{"key":"10.1016\/j.jad.2018.04.047_bib0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","article-title":"Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo","volume":"31","author":"Dunlop","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0036","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/hup.470080306","article-title":"Placebo-Controlled Trial of Paroxetine in Depressive Illness","volume":"8","author":"Edwards","year":"1993","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0037","first-page":"119","article-title":"Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients","volume":"11","author":"Fabre","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl","key":"10.1016\/j.jad.2018.04.047_bib0038","first-page":"40","article-title":"A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients","volume":"53","author":"Fabre","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0039","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/0006-3223(95)00178-8","article-title":"Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo","volume":"38","author":"Fabre","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.jcp.0000178416.60426.29","article-title":"A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder","volume":"25","author":"Fava","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0041","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-198907000-00006","article-title":"A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression","volume":"4","author":"Feighner","year":"1989","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00004850-198904000-00004","article-title":"A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression","volume":"4","author":"Feighner","year":"1989","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0043","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4088\/JCP.v60n1204","article-title":"Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression","volume":"60","author":"Feighner","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0044","doi-asserted-by":"crossref","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis","volume":"155","author":"Gartlehner","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2018.04.047_bib0045","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/03007995.2011.609540","article-title":"Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study","volume":"27","author":"Gaynor","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2018.04.047_bib0046","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1185\/03007995.2011.609539","article-title":"A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms","volume":"27","author":"Gaynor","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2018.04.047_bib0047","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/JCP.v63n0309","article-title":"Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial","volume":"63","author":"Goldstein","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0048","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","article-title":"Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial","volume":"11","author":"Goodman","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0049","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder","volume":"52","author":"Greist","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0050","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00213-013-3316-1","article-title":"A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression","volume":"231","author":"Hantsoo","year":"2014","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jad.2018.04.047_bib0051","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004850-199300840-00007","article-title":"A double-blind trial of fluoxetine, 20\u00a0mg, and placebo in out-patients with DSM-III-R major depression and melancholia","volume":"8","author":"Heiligenstein","year":"1993","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0052","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0053","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0269881108100254","article-title":"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder","volume":"24","author":"Hewett","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0054","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0269881108089602","article-title":"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"23","author":"Hewett","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0055","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0269881109106953","article-title":"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"24","author":"Hewett","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0056","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004714-199310000-00004","article-title":"Effect of fluvoxamine on panic disorder","volume":"13","author":"Hoehn-Saric","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0057","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","article-title":"Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine","volume":"64","author":"Hollander","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0058","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/PSY.0b013e31814b260d","article-title":"Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine","volume":"69","author":"Honig","year":"2007","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.jad.2018.04.047_bib0059","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.pra.0000426323.59698.64","article-title":"Efficacy and safety of desvenlafaxine 25 and 5050% shaded block\u00a0mg\/day in a randomized, placebo-controlled study of depressed outpatients","volume":"19","author":"Iwata","year":"2013","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.jad.2018.04.047_bib0060","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10\u00a0mg and 20\u00a0mg in adults with major depressive disorder","volume":"76","author":"Jacobsen","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0061","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5\u00a0mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0062","first-page":"923","article-title":"Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo","volume":"147","author":"Jenike","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0063","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/ajp.147.9.1209","article-title":"A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory","volume":"147","author":"Jenike","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0064","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1440-1819.2004.01278.x","article-title":"Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients","volume":"58","author":"Kamijima","year":"2004","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2018.04.047_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"Kasper","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0066","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0067","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0068","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4088\/JCP.10m06596","article-title":"A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder","volume":"72","author":"Khan","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.jad.2018.04.047_bib0069","first-page":"27","article-title":"A double-blind, placebo-controlled study of paroxetine in depressed outpatients","volume":"53","author":"Kiev","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study","volume":"22","author":"Kobak","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0071","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00004714-199904000-00013","article-title":"Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder","volume":"19","author":"Kronig","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0072","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2018.04.047_bib0073","first-page":"24","article-title":"Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial","volume":"25","author":"Leinonen","year":"2000","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.jad.2018.04.047_bib0074","first-page":"772","article-title":"A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care","volume":"53","author":"Lenox-Smith","year":"2003","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.jad.2018.04.047_bib0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2008.977","article-title":"Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial","volume":"301","author":"Lenze","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2018.04.047_bib0076","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v59n1006","article-title":"A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder","volume":"59","author":"Lepola","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0077","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/add.12108","article-title":"A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders","volume":"108","author":"Levin","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2018.04.047_bib0078","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00004850-200309000-00009","article-title":"Migraine headache prophylaxis and treatment with low-dose mirtazapine","volume":"18","author":"Levy","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0079","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-244X-13-94","article-title":"A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50\u00a0mg\/day in adult outpatients with major depressive disorder","volume":"13","author":"Liebowitz","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0080","first-page":"194","article-title":"A fixed-dose (300\u00a0mg) efficacy study of bupropion and placebo in depressed outpatients","volume":"51","author":"Lineberry","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0081","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"Londborg","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0082","first-page":"68","article-title":"Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression","volume":"25","author":"Lydiard","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2018.04.047_bib0083","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JNN.0000000000000144","article-title":"The treatment of migraine headache in the presence of selective serotonin reuptake inhibitor use: pharmacokinetic considerations","volume":"47","author":"Macca","year":"2015","journal-title":"J. Neurosci. Nurs."},{"key":"10.1016\/j.jad.2018.04.047_bib0084","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5\u00a0mg and 5\u00a0mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2018.04.047_bib0085","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jad.2018.04.047_bib0086","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2018.04.047_bib0087","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10\u00a0mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0088","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.phymed.2015.01.010","article-title":"Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial","volume":"22","author":"Mao","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jad.2018.04.047_bib0089","first-page":"200","article-title":"A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression","volume":"51","author":"March","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/YIC.0000000000000057","article-title":"Efficacy and safety of vilazodone 20 and 40\u00a0mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Mathews","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0091","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0092","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10194-010-0290-4","article-title":"Primary headaches in patients with generalized anxiety disorder","volume":"12","author":"Mercante","year":"2011","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.jad.2018.04.047_bib0093","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0094","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20\u00a0mg, 40\u00a0mg and 60\u00a0mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-199803000-00002","article-title":"Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study","volume":"13","author":"Montgomery","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0096","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine","volume":"67","author":"Montgomery","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0097","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"key":"10.1016\/j.jad.2018.04.047_bib0098","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl 2","key":"10.1016\/j.jad.2018.04.047_bib0099","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/head.13083","article-title":"Neuropeptides and Neurotransmitters That Modulate Thalamo-Cortical Pathways Relevant to Migraine Headache","volume":"57","author":"Noseda","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.jad.2018.04.047_bib0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.167.3.374","article-title":"Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study","volume":"167","author":"Oehrberg","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0101","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","article-title":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"21","author":"Perahia","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0102","first-page":"95","article-title":"Bupropion in depression: a tri-center placebo-controlled study","volume":"44","author":"Pitts","year":"1983","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0103","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0104","first-page":"667","article-title":"Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study","volume":"32","author":"Pollack","year":"1996","journal-title":"Psychopharmacol. Bull."},{"issue":"Suppl B","key":"10.1016\/j.jad.2018.04.047_bib0105","first-page":"18","article-title":"Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression","volume":"51","author":"Reimherr","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0106","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0149-2918(98)80060-X","article-title":"A multicenter evaluation of the efficacy and safety of 150 and 300\u00a0mg\/d sustained-release bupropion tablets versus placebo in depressed outpatients","volume":"20","author":"Reimherr","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2018.04.047_bib0107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0447.1989.tb07188.x","article-title":"A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients","volume":"350","author":"Rickels","year":"1989","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jad.2018.04.047_bib0108","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.08m04637","article-title":"Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Rickels","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0109","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.euroneuro.2016.08.012","article-title":"H1-histamine receptor affinity predicts weight gain with antidepressants","volume":"26","author":"Salvi","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/lary.25445","article-title":"Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial","volume":"126","author":"Salviz","year":"2016","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jad.2018.04.047_bib0111","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00004850-200015060-00004","article-title":"The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies","volume":"15","author":"Sheikh","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4088\/JCP.v62n07a04","article-title":"Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder","volume":"62","author":"Silverstone","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.jad.2018.04.047_bib0113","first-page":"36","article-title":"A placebo-controlled trial of paroxetine in the treatment of major depression","volume":"53","author":"Smith","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0114","first-page":"191","article-title":"Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder","volume":"26","author":"Smith","year":"1990","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2018.04.047_bib0115","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0116","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0117","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2018.04.047_bib0118","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2018.04.047_bib0119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/WNF.0b013e3181a8c84f","article-title":"Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders","volume":"32","author":"Tarlaci","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Pt 1","key":"10.1016\/j.jad.2018.04.047_bib0121","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100\u00a0mg\/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31","author":"Tourian","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2018.04.047_bib0122","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10\u00a0mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"17","author":"Wade","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0123","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","article-title":"The effect of citalopram in panic disorder","volume":"170","author":"Wade","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.04.047_bib0124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder","volume":"24","author":"Westenberg","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.04.047_bib0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000368559","article-title":"Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial","volume":"94","author":"Zhang","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.jad.2018.04.047_bib0126","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators","volume":"169","author":"Zohar","year":"1996","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718301241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718301241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T11:51:30Z","timestamp":1530705090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718301241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":126,"alternative-id":["S0165032718301241"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2018.04.047","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis: Second generation antidepressants and headache","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2018.04.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}